Indication intelligence, analysis and sector perception

Lower open expected, a continued recovery in “our” universe is a bumpy road

January 21, 2016 6:40am

Which is worse, a bad day or the oral surgeon’s chair – loved the anesthesia!

I missed yesterday’s finale as the oral surgeon reshaped my jaw – talk next week, back to bed!

Haven’t been wrong, understand WHY, the time has come to SUBSCRIBE! Can you afford not to?

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors before the sector and markets open. But, who is interpreting that information … get it here!

DOW futures and NASDAQ futures are DOWN -0.5%

U.S. stock index futures pointed to more losses on Thursday, with Dow futures down as much as 100 points in premarket trading as concerns surrounding global growth, uncertainty in China and fresh lows in oil prices continued to grip markets.

European stocks wobbled in early trading, ahead of the European Central Bank's (ECB) monthly policy meeting, as investors hoped for some reassurance from President Mario Draghi amid severe volatility in global markets.

Asia markets extended losses, with the Nikkei ending around 2.4% lower. That leaves the index deeper into bear territory after losing 3.71% in Wednesday's session. China's main Shanghai Composite ended over 3% lower, while the Shenzhen tumbled over 4%.

Data docket: The usual initial claims data is due at 8:30 a.m. ET, along with the Philadelphia Fed index also released at 8:30 a.m.

The stem, cell and gene therapy RegMed sector closed POSITIVE on Wednesday afer NEGATIVE closes on Tuesday and Friday post a POSITIVE close on last Thursday.

Past five (5) days:

· Wednesday closed POSITIVE with 8 decliners, 34 advancers and 1 flat

· Tuesday closed NEGATIVE with 34 decliners, 9 advancers and 0 flats;

· Monday was the Martin Luther King Jr. holiday;

· Friday closed NEGATIVE with 33 decliners, 8 advancers and 1 flat;

· Last, Thursday closed POSITIVE with 13 decliners and 30 advancers;

Wall Street was setting up for another volatile session on Thursday as stock futures seesawed lower, overshadowed by sharp losses for Asian stocks and continued pressure on oil prices.

Reiterating, investors have slogged through the last months, the stem, cell and gene therapy RegMed (SCGT&RM) sector as - there is always light at the end of the tunnel with some of the brightness illuminating the final steps.

The best way to profit on the SCGT&RM sector is to see which company has dumped the most share pricing – it’s still a credibility issue and start reading our reviews.

Reiterating, as a solid advocate of the sector, I point-out that truth is stranger than fiction but, regardless of the idiom - “our” universe should be bracing for a grim financial reporting season, notice I didn’t say - earnings.

Sorry, couldn’t do Thursday’s indications … serious jaw issues:

Wednesday’s indications were on target though - 7 hits, 3 miss:

Applied Genetic Technologies (AGTC) closed UP +$0.96 – hit;
Bellicum Pharma (BLCM) closed UP +$1.16 – hit;
bluebird bio (BLUE) closed UP – miss;
Capricor (CAPR) closed UP +$0.11 – miss;
Fate Therapeutics (FATE) closed UP +$0.0125 – hit;
Harvard Apparatus RT (HART) closed DOWN -$0.069– hit;
Histogenics (HSGX) closed DOWN - $0.28 – miss;
Juno Therapeutics (JUNO) closed UP +$1.54 – hit;
Spark Therapeutics (ONCE) closed UP +$3.66 – hit;
Verastem (VSTM) closed UP +$0.18 – hit;

Remember, the perils of confusing correlation and causation!

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.